Shionogi Deal History & Licensing Activity
Shionogi is a mid-size pharma headquartered in JP. Over the past three years, Shionogi has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 17 active clinical trials, primarily in Other.
Deals (12mo)
1
Active Trials
17
Top Modality
Small Molecules
Focus Area
Other
Shionogi Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Shionogi in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Shionogi-Apnimed Sleep Science (SASS) joint venture stake | Apnimed | Small Molecules | Phase 2 | acquisition | Mar 2026 |
Shionogi Pipeline Focus
Therapeutic areas and modalities where Shionogi is most active based on deal history and clinical trial data.
Therapeutic Areas
Shionogi Strategic Signals
Key indicators of Shionogi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Shionogi Clinical Pipeline
Shionogi has 17 active clinical trials across 5 development phases.
1
Phase 4
1
Not Applicable
8
Phase 1
6
Phase 2
1
Phase 3
See How Your Asset Matches Shionogi's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Shionogi Licensing & Deal Activity
Shionogi is a mid-size pharma company based in JP that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Shionogi ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Shionogi include Other (2 deals and trials), Infectious (2 deals and trials), CNS Disorders (2 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Shionogi has shown particular interest in small molecules, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Shionogi and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Shionogi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.